[Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
Osanto
S
S
Brand
A
A
van Rood
J J
JJ
Cleton
F J
FJ
D002986:Clinical Trials as Topic; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2
Immunotherapie van kanker met interleukine-2 en met interleukine-2 geactiveerde cellen.